

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039812 A1

(51) International Patent Classification⁷: **C07D 501/04**

(21) International Application Number:
PCT/IB2002/005459

(22) International Filing Date:
18 December 2002 (18.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
800/MAS/2002 30 October 2002 (30.10.2002) IN

(71) Applicant (for all designated States except US): **ORCHID
CHEMICALS & PHARMACEUTICALS LIMITED**
[IN/IN]; 1, 6th Floor, Crown Court, 34, Cathedral Road,
600 086 Chennai (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DESHPANDE,
Pandurang, Balwant** [IN/IN]; F-3, Sand Stone Apart-
ment, First Avenue, Indira Nagar, 600 020 Chennai (IN).
KHADANGALE, Bhausaheb, Pandharinath [IN/IN];
Santhi Avenue, No.7, Dr. Radhakrishnan Road, Thiru-
vanmiyur, 600 041 Chennai (IN). **GURUSAMY, Kumar**
[IN/IN]; Plot NO.33, V.O.C. Nagar, Mahalaxmi Nagar,
Selayur, 600 073 Chennai (IN). **KONDA, Ramesh,**
Athimaram [IN/IN]; New No.5, Ashtabujam First Lane,
Choolai, 600 112 Chennai (IN).

(74) Agent: **SRINIVASAN, Thiagarajan; Kumaran & Sagar,**
84-C, C6 Lane, Off Central Avenue, Sainik Farms, 110 062
New Delhi (IN).

(81) Designated States (national): AF, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **PROCESS FOR THE PREPARATION OF 3-PROPENYL CEPHALOSPORIN DMF SOLVATE**



(I)


(57) Abstract: The present invention relates to an
improved process for the preparation of 3-propenyl
cephalosporin DMF solvate, more particularly, the
present invention relates to an improved process
for the preparation of cefprozil DMF solvate of the
formula (I), which is useful for the preparation of
cefprozil of the formula (XIV).

WO 2004/039812 A1


PROCESS FOR THE PREPARATION OF 3-PROPENYL CEPHALOSPORIN DMF SOLVATE

Technical Field

The present invention relates to an improved process for the preparation of 3-propenyl cephalosporin DMF solvate. More particularly, the present invention relates to an improved process for the preparation of cefprozil DMF solvate of the formula (I).




The 3-propenyl cephalosporin DMF solvate of the formula (I) is useful for the preparation of cefprozil of the formula (XIV).

**Background of the Invention**

Cefprozil is chemically known as (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid. It is an orally effective cephalosporin antibiotic having a broad spectrum of antibacterial activity against both gram positive and gram-negative organisms and is disclosed in US Patent No. 4,520,022.

US patent No. 4,694,079 discloses a process for the preparation of DMF solvate of cefprozil as shown in scheme I below :



US patent No. 5,608,055 discloses a process for the production of 7- α -aminoacyl-cephalosporin by acylating 7-amino-3-cephem-4-carboxylic acid or a derivative thereof in a halogen-free solvent. The yields in the process are very low.

i) preparing a (Z)-isomer enriched 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid (APCA) by depleting 7-amino-3-{(E)-1-propen-1-yl}-3-cephem-4-carboxylic acid in a Z/E mixture of 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid

- a) by forming the hydrochloride of APCA in a solvent or solvent mixture and recovering the enriched Z-isomer and optionally converting the hydrochloride into the free acid with reduced E amount by adjusting the pH, or forming a salt of APCA and converting the salt to APCA with reduced E amount or subjecting the solution of APCA to adsorption chromatography, and
- ii) acylating the (Z)-isomer enriched 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid in free acid or salt form obtained in step (i) at the amine group in position 7 of the ring system to obtain cefprozil. This patent discloses different salts of APCA and the preparation of cefprozil using these salts. The salts disclosed are lithium, sodium, potassium, ammonium, cyclohexyl amine, dicyclohexyl amine. The Z/E ratio of the

product before the chromatography or further purification is 85/15. After purification the Z-isomer ratio is increased to greater than 90%.

One of the process described uses adsorption chromatography for the separation of isomers, which is cannot be done on industrial scale very easily. The other processes uses further crystallization for getting enriched (Z) isomer, which involves use of high volumes of solvent.

With the process described in the prior art, it is not possible to obtain the high isomeric purity. The product obtained by all the processes contains very high content of (E) isomer. We, therefore, focussed our research to identify a process, which gives product with high isomeric purity.

Objective of the Invention

The main objective of the present invention is to provide an improved process for the preparation of 3-propenyl cephalosporin DMF solvate of the formula (I).

Another objective of the present invention is to provide a stable process for the preparation of 3-propenyl cephalosporin DMF solvate of the formula (I) with (Z)-isomer enrichment.


Yet another objective of the present invention is to provide a stable process for the preparation of 3-propenyl cephalosporin DMF solvate of the formula (I) using halogenated solvents in high purity and yield.

Yet another objective of the present invention is to provide a stable process for the preparation of 3-propenyl cephalosporin DMF solvate of the formula (I), which avoids the use of adsorption chromatography or recrystallization methods in any stage of the process and easy to operate on industrial scale.

Yet another objective of the present invention is to provide a process for the preparation of cefprozil using 3-propenyl cephalosporin DMF solvate of the formula (I).

Summary of the Invention


Accordingly, the present invention provides an improved process for the preparation of cefprozil DMF solvate of the formula (I)



comprising the steps of :

- i) converting the compound of formula (VII) wherein R_1 represents carboxy protecting group to a compound of the formula (VIII) using triphenylphosphine in the presence of solvent and alkali iodide,
- ii) reacting the compound of formula (VIII) with acetaldehyde using lithium chloride in the presence of solvent at a temperature in the range of $-10\text{ }^{\circ}\text{C}$ to $30\text{ }^{\circ}\text{C}$ to produce a compound of formula (IX) wherein R_1 is as defined above,
- iii) deesterifying the carboxy protecting group of compound of the formula (IX) using an acid in the presence of solvent at a temperature in the range of $10\text{ }^{\circ}\text{C}$ to $50\text{ }^{\circ}\text{C}$ to yield compound of formula (X),
- iv) converting the compound of formula (X) to compound of formula (XI) wherein M^+ represents a counter ion which forms a salt in the presence of a base and solvent,
- v) neutralizing the compound of formula (XI) followed by enzymatic hydrolysis to produce APCA of formula (V), using conventional methods,
- vi) silylating the APCA of formula (V) using a mixture of trimethyl silylchloride and hexamethyl disilazane in the presence of a halogenated solvent to produce silylated APCA of formula (XII) and
- vii) condensing the silylated derivative of APCA of the formula (XII) with the mixed anhydride of the formula (XIII) wherein R_2 represents alkyl, phenyl, benzyl or cycloalkyl and R_3 represents methyl, ethyl or isopropyl, in the presence of a halogenated solvent and a base at a temperature in the range of $-70\text{ }^{\circ}\text{C}$ to $10\text{ }^{\circ}\text{C}$ to produce cefprozil DMF solvate of formula (I).

The process is shown in Scheme-2



Scheme-2

Detailed description of the invention

In an embodiment of the present invention, the carboxy protecting group represented by R^1 is selected from $(\text{C}_1\text{-C}_6)$ alkyl group such as methyl, ethyl, propyl, isopropyl, t-butyl and the like; p-methoxybenzyl, p-nitrobenzyl, o-chlorobenzyl, diphenylmethyl and the like.

In yet another embodiment of the present invention, the solvent used in step (i) is selected from methylene chloride, acetone, water and the like or mixtures thereof.

In an embodiment of the present invention, the alkali iodide used in step (i) is selected from sodium iodide, lithium iodide or potassium iodide.

In an embodiment of the present invention, the reaction with acetaldehyde in step (ii) is carried out using solvents such as DMF, isopropyl alcohol, methylene chloride, acetone, acetonitrile and the like or mixtures thereof.

In an embodiment of the present invention, the reaction with acetaldehyde in step (ii) is carried out preferably at a temperature in the range of $0\text{-}5^\circ\text{C}$.

In yet another embodiment of the present invention, the deesterification in step (iii) is carried out using phenol, phenol/trifluoroacetic acid, anisole/trifluoroacetic acid, formic acid using solvent such as methylene chloride, ethyl acetate, water and the like or mixtures thereof.

In yet another embodiment of the present invention, the conversion in step (iv) is carried out in the presence of solvent selected from water, acetone, DMF, THF, DMAc, DMSO, halogenated alkanes like methylene chloride, ethylene chloride, CCl₄, CHCl₃ and the like or mixtures thereof using base such as inorganic base like sodium hydroxide, lithium hydroxide, potassium hydroxide, ammonium hydroxide or organic base such as tertiary butyl amine, benzyl amine, dibenzyl amine, diethyl amine, triethyl amine, dicyclohexyl amine, cyclohexyl amine, benzothiazole and the like.

In an embodiment of the present invention, the neutralization in step (v) is carried out using solvents such as ethyl acetate, water and like or mixture thereof.


In an embodiment of the present invention, the neutralization in step (v) is carried out using ammonia.

In an embodiment of the present invention, the enzymatic hydrolysis in step (v) is carried out using PenG-amidase.

In yet another embodiment of the present invention, the silylation in step (vi) is carried out in the presence of halogenated solvents such as methylene chloride, ethylene chloride, CCl₄, CHCl₃ and the like.


In yet another embodiment of the present invention, the condensation in step (vii) is carried out in the presence of halogenated solvents such as methylene chloride, ethylene chloride, CCl₄, CHCl₃ and the like and base such as triethylamine, N-methyl morpholine, diethylamine and the like.

In another embodiment of the present invention, there is provided a process for the preparation of cefprozil of the formula (XIV)




from cefprozil DMF solvate of the formula (I) by known methods.

In yet another embodiment of the present invention, the mixed anhydride of the formula (XIII) is prepared from Dane salt of formula (XV)




wherein R_3 represents methyl, ethyl or isopropyl and Y^+ is sodium or potassium and chloroformate of formula (XVI)



wherein R_2 represents alkyl, phenyl, benzyl or cycloalkyl in the presence of solvents selected from mixture of methylene chloride/dimethyl acetamide, ethylene chloride/dimethyl acetamide, methylene chloride/DMF, ethylene chloride/DMF and the like and catalyst such as N-methyl morpholine.

In yet another embodiment of the present invention, there is provided an intermediate of formula (XI)



wherein M^+ represents a counter ion which forms a salt.

In yet another embodiment of the present invention, the counter ion represented by M^+ is selected from sodium, potassium, lithium, ammonium tertiary butyl amine, benzyl amine, dibenzyl amine, diethyl amine, triethyl amine, dicyclohexyl amine, benzothiazole and the like.

The compound of formula (XI) obtained is enriched in (Z) isomer. Using this compound as an intermediate for the preparation of compound of formula (I), we could achieve the preparation of compound of formula (I) with enriched (Z) isomer.

The advantage of using the combination of HMDS and trimethyl silyl chloride as a silylating agent is that the reaction is faster and the formation of impurities is less.

The present invention is provided by the examples given below, which are provided by way of illustration only and should not be considered to limit the scope of the invention.

Example 1

Step (i)

Preparation of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII)

To a suspension of 4-methoxybenzyl 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylate (VII) (100g, 0.2053mol) in methylene chloride (600ml), NaI (32.3g, 0.2155mol), triphenylphosphine (56.6g, 0.2157mol) and water (600ml) were added. The mixture was stirred at 32 to 35°C under nitrogen atmosphere for 90 min. The organic layer was separated and 1N NaOH (217ml) was added. The resulting reddish brown mixture was stirred at 30 to 32°C for 20 min. The organic layer was separated and washed with water (500ml) followed by 20%w/w aq. NaCl solution (500ml). The organic layer was diluted upto 1000ml using fresh methylene chloride. The title compound (VIII) in methylene chloride used as such in the next reaction.

Step (ii)

Preparation of 4-methoxybenzyl 7-phenylacetamido-3-((Z/E-propen-1-yl)-3-cephem-4-carboxylate (IX)

To a cold suspension of lithium chloride (26.2g, 0.618mol) in dry DMF (100ml), the solution of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII) obtained in step (i) in methylene chloride (1000ml) was added. The resulting solution was cooled to 0 to 5°C. Acetaldehyde (139ml, 2.46mol) was added to the above mixture at 0 to 5°C. The reaction mixture was stirred for 18 hrs at 0 to 5°C and water (400ml) was added and stirred at 10 to 15°C for 10min. The organic layer was separated, concentrated under vacuum and washed. To this concentrate, IPA (800ml) was added at 30°C and stirred to get the precipitate of (IX). Water (900ml) was added and filtered to yield the title compound (yield 86g, purity 92.6%, Z/E ratio 92.4/7.5, by HPLC).

Step (iii)

Preparation of 7-phenylacetamido-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid (X)

4-Methoxybenzyl 7-phenylacetamido-3-((Z/E)-propen-1-yl)-3-cephem-4-carboxylate obtained in step (ii) (50g) was dissolved in phenol (50ml) and trifluoroacetic acid (TFA) (14.5g). The reaction mixture was stirred at 30 to 35°C for 4 to 5 hrs and transferred to a mixture of water (250ml) and ethyl acetate (250ml) at 20°C. The pH was adjusted to 8.0 using 2N NaOH solution. The organic layer was separated and aq. layer was extracted with ethyl acetate (50ml). The combined aq. layer was charcoalised and filtered. pH of the filtrate was adjusted to 2.0 to 2.5 with 15% sulfuric acid and stirred for 30min. Filtered and washed with water (2x50ml) to yield the title compound (yield (wet) 74g, purity 97.6%, Z/E ratio 90.0/10.0, by HPLC).

Step (iv)**Preparation of 7-phenylacetamido-3-[(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid dicyclohexylamine salt (XI)**

7-Phenylacetamido-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid obtained in step (iii) above (5g) dissolved in acetone (80ml) and water (40ml). To this solution dicyclohexylamine (2.5g) was added, stirred and filtered through suction and washed with ethyl acetate (10ml) to yield the title compound (yield 2.5g, purity : 99.6%, Z/E ratio 93.7/6.3, by HPLC).

Step (v)**Preparation of 7-amino-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid (V)**

7-Phenylacetamido-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid dicyclohexylamine salt (100g) prepared according to the process described in step (iv) was taken in ethyl acetate (1.6lt) and water (1.0lt). pH of resulted slurry was adjusted to 2.0 using 15% sulfuric acid. The layers were separated. To the ethyl acetate layer, water (1.0lt) was added and pH was adjusted to 8.0 using 10% ammonia solution. The layers were separated and the aqueous layer was washed with butyl acetate (250ml). To the aqueous layer, PenG-amidase (48g, dry basis) was added. pH was maintained between 7.8 and 8.0 using 5% ammonia for 4 to 5 hrs. PenG-amidase was separated by filtration and the filtrate was treated with activated carbon. Carbon was filtered off and pH of the filtrate was adjusted to 3.5 using 1:1 HCl solution at 30°C. The precipitate was stirred, filtered and washed with water (2x60ml) and dried to yield the title compound (yield 39g, purity 99.2%, Z/E ratio 92.3/7.7).

Step (vi)**Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I)**

7-Amino-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid (V) (50g, 0.2081mol) prepared according to the process described in step (v) was stirred in methylene chloride (250ml) at 30°C. Tetramethylchlorosilane (17.3g, 0.1594mol) and hexamethyldisilazane (25.75g, 0.1594mol) were added and stirred for 2hrs at 30 to 35°C to form compound (XII) in situ. Then cooled to -10°C.

Simultaneously, p-hydroxy phenyl glycine Dane salt (67.4g, 0.2223mol) in methylene chloride (350ml) was stirred and cooled to -10°C. DMF (120ml) was added and further cooled to -45°C. N-methylmorpholine (0.5ml) and ethylchloroformate (24.8g, 0.2285mol) were added and stirred for 1.5hrs at -40°C to -45°C to form compound (XIII).

The cold mixture of compound (XII) was added into compound (XIII) at -60°C . The resulting slurry was stirred at -45°C to -50°C for 1.5hrs. 1:1 HCl (55ml) and water (100ml) were added at -45°C . The temperature was gradually allowed to raise to 5°C and stirred for 10min. The aq. layer was separated, the organic layer was extracted with 1:1 HCl solution (10ml) and the combined aq. layers were cooled to 0 to 5°C . DMF (600ml) and IPA (300ml) were added and stirred at 0 to 5°C for 10min. and filtered. The filtrate was warmed to 30°C , triethylamine was added rapidly to adjust the pH to 6 at 30 to 35°C . The slurry was stirred at 0 to 5°C for 1hr. The precipitate was filtered and washed with IPA (80ml) followed by acetone (300ml). The wet material was air dried to yield the title compound (yield 110.4g, purity 97.69, moisture content 3.4%, Z/E ratio 92.3/7.7).

Step (vii)

Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid monohydrate (XIV)

(6R,7R)-7-[2-Amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I) (110g) was stirred in water (160ml) at 30°C for 40min. The Crude compound was collected by filtration and washed with water (30ml) followed by acetone (30ml). The wet crude was dried in vacuum at room temperature to give dried material which was then stirred in water (140ml) at 15°C , pH was adjusted to 1.0 using 1:1 HCl to get clear solution. Then pH was readjusted to 5.0 using 10% ammonia solution at 15 to 20°C . The precipitate was cooled to 2 to 5°C , stirred for 1.5hr, filtered and washed with water (30ml) followed by acetone (30ml) and dried in vacuum at room temperature to give the title compound (yield 65g, 98.96%pure, moisture content 5.5%, Z/E ratio 91.5/8.5).

Example 2

Step (i)

Preparation of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII)

To a stirred suspension of 4-methoxybenzyl 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylate (VII) (10g, 0.0205mol) in acetone (50ml), sodium iodide (3.1g, 0.0207mol) and triphenylphosphine (5.9g, 0.0226mol) were added. The mixture was stirred at 30 to 32°C for 1.5hrs. The resulting mixture was concentrated in vacuo to get the residual oil. To this concentrate methylene chloride (50ML) was added and to the resultant solution, 2N NaOH solution (20ml) was added and stirred at 30 to 32°C for 20min. The

organic layer was separated and washed with water (25ml) and dried over anhydrous sodium sulfate to give the title compound (VIII) in methylene chloride.

Step (ii)

Preparation of 4-methoxybenzyl 7-phenylacetamido-3-((Z/E-propen-1-yl)-3-cephem-4-carboxylate (IX)

To a cold suspension of lithium chloride (26.2g, 0.6179mol) in dry DMF (100ml), the solution of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII) obtained according to the process described in step (i) in methylene chloride (1000ml) was added. The resulting solution was cooled to 0 to 5°C. Acetaldehyde (139ml, 2.48mol) was added to the above mixture at 0 to 5°C. The reaction mixture was stirred for 18 hrs at 0 to 5°C and water (400ml) was added and stirred at 10 to 15°C for 10min. The organic layer was separated, concentrated under vacuum and washed. To this concentrate, IPA (800ml) was added at 30°C and stirred to get the precipitate of (IX). Water (900ml) was added and filtered to yield the title compound (yield 86g, purity 93%, Z/E ratio 92.2/7.8).

Step (iii)

Preparation of 7-phenylacetamido-3-[(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid dicyclohexylamine salt (XI)

4-Methoxybenzyl 7-phenylacetamido-3-((Z/E-propen-1-yl)-3-cephem-4-carboxylate obtained in step (ii) above (50g) was dissolved in phenol (50ml) and TFA (14.25g) and it was stirred at 30 to 35°C for 3 to 4hrs. The mixture was added to cold mixture of water (250ml) and ethyl acetate (250ml), pH was adjusted to 8.0 using 2N NaOH solution at 20-22°C. The aq. layer was separated and ethyl acetate (400ml) was added and the pH was adjusted to 2.0 to 2.3 using 15%w/v sulfuric acid. The upper ethyl acetate layer was separated and to this water (300ml) and acetone (50ml) were added. Dicyclohexylamine was added in drops and pH adjusted to 5.0. Subsequently the resultant precipitate was stirred, filtered, washed with ethyl acetate (50ml) and dried to give the title compound (yield (dry) 35g, purity 99.6%, Z/E ratio 94.6/5.4).

Step (iv)

Preparation of 7-amino-3-((Z/E)-propen-1-yl)-3-cephem-4-carboxylic acid (V)

7-Phenylacetamido-3-[(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid dicyclohexylamine salt (100g) prepared according to the process described in step (iii) was taken in ethyl acetate (1.6lt) and water (1.0lt). pH of resulted slurry was adjusted to 2.0 using 15%

sulfuric acid. The layers were separated. To the ethyl acetate layer water (1.0lt) was added and pH was adjusted to 8.0 using 10% ammonia solution. The layers were separated and the aqueous layer was washed with butyl acetate (250ml). To the aqueous layer, PenG-amidase (48g, dry basis) was added. pH was maintained between 7.8 and 8.0 using 5% ammonia for 4 to 5 hrs. PenG-amidase was separated by filtration and filtrate was treated with activated carbon. Carbon was filtered off and pH of the filtrate was adjusted to 3.5 using 1:1 HCl solution at 30°C. The precipitate was stirred, filtered and washed with water (2x60ml) and dried to yield the title compound (yield 39g, purity 98.2%, Z/E ratio 93.6/6.4).

Step (v)

Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I)

7-Amino-3-((Z/E)-propen-1-yl)-3-cephem-4-carboxylic acid (V) (50g, 0.2081mol) prepared according to the process described in step (iv) was stirred in methylene chloride (250ml) at 30°C. Tetramethylchlorosilane (17.3g, 0.1594mol) and hexamethyldisilazane (25.75g, 0.1594mol) were added and stirred for 2hrs at 30 to 35°C to form compound (XII) in situ. Then cooled to -10°C.

Simultaneously, p-hydroxy phenyl glycine Dane salt (67.4g, 0.2223mol) in methylene chloride (350ml) was stirred and cooled to -10°C. DMF (120ml) was added and further cooled to -45°C. N-methylmorpholine (0.5ml) and methylchloroformate (21.59g, 0.2285mol) were added and stirred for 1.5hrs at -40°C to -45°C to form compound (XIII).

The cold mixture of compound (XII) was added into compound (XIII) at -60°C. The resulting slurry was stirred at -45°C to -50°C for 1.5hrs. 1:1 HCl (55ml) and water (100ml) were added at -45°C. The temperature was gradually allowed to raise to 5°C and stirred for 10min. The aq. layer was separated, the organic layer was extracted with 1:1 HCl solution (10ml) and the combined aq. layers were cooled to 0 to 5°C. DMF (600ml) and IPA (300ml) were added and stirred at 0 to 5°C for 10min. and filtered. The filtrate was warmed to 30°C, triethylamine was added rapidly to adjust the pH to 6 at 30 to 35°C. The slurry was stirred at 0 to 5°C for 1hr. The precipitate was filtered and washed with IPA (80ml) followed by acetone (300ml). The wet material was air dried to yield the title compound (yield 110.4g, moisture content 3.4%, purity 97.4%, Z/E ratio 91.8/8.2).

Step (vi)**Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid monohydrate (XIV)**

(6R,7R)-7-[2-Amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I) (110g) was stirred in water (160ml) at 30°C for 40min. The Crude compound was collected by filtration and washed with water (30ml) followed by acetone (30ml). The wet crude was dried in vacuum at room temperature to give dried material which was then stirred in water (140ml) at 15°C, pH was adjusted to 1.0 using 1:1 HCl to get clear solution. Then pH was readjusted to 5.0 using 10% ammonia solution at 15 to 20°C. The precipitate was cooled to 2 to 5°C, stirred for 1.5hr, filtered and washed with water (30ml) followed by acetone (30ml) and dried in vacuum at room temperature to give the title compound (yield 65g, moisture content 5.5%, purity 98.45%, Z/E ratio 91.3/8.7).

Example 3**Step (i)****Preparation of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII)**

To a suspension of 4-methoxybenzyl 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylate (VII) (100g, 0.2053mol) in methylene chloride (600ml), NaI (32.3g, 0.2155mol), triphenylphosphine (56.6g, 0.2155mol) and water (600ml) were added. The mixture was stirred at 32 to 35°C under nitrogen atmosphere for 90 min. The organic layer was separated and 1N NaOH (217ml) was added. The resulting reddish brown mixture was stirred at 30 to 32°C for 20 min. The organic layer was separated and washed with water (500ml) followed by 20%w/w aq. NaCl solution (500ml). The organic layer was diluted upto 1000ml using fresh methylene chloride. The title compound (VIII) in methylene chloride used as such in the next reaction.

Step (ii)**Preparation of 4-methoxybenzyl 7-phenylacetamido-3-[(Z/E-propen-1-yl)-3-cephem-4-carboxylate (IX)**

To a cold solution of 4-methoxybenzyl 7-phenylacetamido-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VIII) obtained in step (i) above in methylene chloride (500ml) lithium chloride (13.1g, 0.3089mole) and dry DMF (50ml) were added. The resulting solution was cooled to 0 to 5°C. Acetaldehyde (69.5ml, 1.24mole) was added to the above mixture at 0 to 5°C. The reaction mixture was stirred for

18 hrs at 0 to 5°C and water (200ml) was added and stirred at 10 to 15°C for 10min. The organic layer was separated, concentrated under vacuum and washed. To this concentrate, IPA (400ml) was added at 30°C and stirred to get the precipitate of (IX). Water (450ml) was added and filtered to yield the title compound (yield 44.6g, purity 93.7%, Z/E ratio 92.2 / 7.8).

Step (iii)

Preparation of 7-phenylacetamido-3-[(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid cyclohexylamine salt (XI)

7-Phenylacetamido-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid obtained in step (ii) above (20g) was dissolved in phenol (20ml) and TFA (5.7g) and it was stirred at 30 to 35°C for 3 to 4hrs. The mixture was added to cold mixture of water (100ml) and ethylacetate (100ml), pH was adjusted to 8.0 using 2N NaOH solution at 20-22°C. The aq. layer was separated and ethylacetate (140ml) was added and the pH was adjusted to 2.0 to 2.3 using 15%w/v sulfuric acid. The upper ethyl acetate layer was separated and to this water (25ml) and acetone (50ml) were added. Cyclohexylamine was added in drops and pH adjusted to 5.5. Subsequently the resultant precipitate was stirred, filtered, washed with ethylacetate (20ml) and dried to give the title compound (yield (dry) 8.2g purity 99.68% Z/E ratio 93.1/ 6.9).

Step (iv)

Preparation of 7-amino-3-((Z/E)-propen-1-yl)-3-cephem-4-carboxylic acid (V)

7-Phenylacetamido-3-[(Z/E)-propen-1-yl]-3-ceph-em-4-carboxylic acid cyclohexylamine salt (100g) prepared according to the process described in step (iii) was taken in ethyl acetate (1.6lt) and water (1.0lt). pH of resulted slurry was adjusted to 2.0 using 15% sulfuric acid. The layers were separated. To the ethyl acetate layer, water (1.0lt) was added and pH was adjusted to 8.0 using 10% ammonia solution. The layers were separated. The aqueous layer was washed with butyl acetate (250ml). To the aqueous layer, PenG-amidase (48g, dry basis) was added. pH was maintained between 7.8 and 8.0 using 5% ammonia for 4 to 5 hrs. PenG-amidase was separated by filtration and the filtrate was treated with activated carbon. Carbon was filtered off and pH of the filtrate was adjusted to 3.5 using 1:1 HCl solution at 30°C. The precipitate was stirred, filtered and washed with water (2x60ml) and dried to yield the title compound (yield 39g).

Step (v)**Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I)**

7-Amino-3-[(Z/E)-propen-1-yl]-3-cephem-4-carboxylic acid (V) (50g, 0.2081mol) was stirred in methylene chloride (250ml) at 30°C. Tetramethylchlorosilane (17.3g, 0.1594mol) and hexamethyldisilazane (25.75g, 0.1594mol) were added and stirred for 2hrs at 30 to 35°C to form compound (XII) in situ. Then cooled to -10°C.

Simultaneously, p-hydroxy phenyl glycine Dane salt (67.4g, 0.2223mol) in methylene chloride (350ml) was stirred and cooled to -10°C. DMF (120ml) was added and further cooled to -45°C. N-methylmorpholine (0.5ml) and ethylchloroformate (24.8g, 0.2285mol) were added and stirred for 1.5 hrs at -40°C to -45°C to form compound (XIII).


The cold mixture of compound (XII) was added into compound (XIII) at -60°C. The resulting slurry was stirred at -45°C to -50°C for 1.5hrs. 1:1 HCl (55ml) and water (100ml) were added at -45°C. The temperature was gradually allowed to raise to 5°C and stirred for 10min. The aq. layer was separated, the organic layer was extracted with 1:1 HCl solution (10ml) and the combined aq. layers were cooled to 0 to 5°C. DMF (600ml) and IPA (300ml) were added and stirred at 0 to 5°C for 10min. and filtered. The filtrate was warmed to 30°C, triethylamine was added rapidly to adjust the pH to 6 at 30 to 35°C. The slurry was stirred at 0 to 5°C for 1hr. The precipitate was filtered and washed with IPA (80ml) followed by acetone (300ml). The wet material was air dried to yield the title compound (yield 110.4g, moisture content 3.4%).

Step (vii)**Preparation of (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid monohydrate (XIV)**

(6R,7R)-7-[2-Amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid DMF solvate (I) (110g) was stirred in water (160ml) at 30°C for 40min. The Crude compound was collected by filtration and washed with water (30ml) followed by acetone (30ml). The wet crude was dried in vacuum at room temp to give dried material which was then stirred in water (140ml) at 15°C, pH was adjusted to 1.0 using 1:1 HCl to get clear solution. Then pH was readjusted to 5.0 using 10% ammonia solution at 15 to 20°C. The precipitate was cooled to 2 to 5°C, stirred for 1.5hr, filtered and washed with water (30ml) followed by acetone (30ml) and dried in vacuum at room temperature to give the title compound (yield 65g, 99.1%pure, moisture content 5.5%).


Claims

1. An improved process for the preparation of cefprozil DMF solvate of the formula (I)




comprising the steps of:

- i) reacting the compound of formula (VIII)




with acetaldehyde using lithium chloride in the presence of solvent at a temperature in the range of -10°C to 30°C to produce a compound of formula (IX)




wherein R_1 is as defined above,

- ii) deesterifying the carboxy protecting group of compound of the formula (IX) using an acid in the presence of solvent at a temperature in the range of 10°C to 50°C to yield compound of formula (X),




- iii) converting the compound of formula (X) to compound of formula (XI)




wherein M^{+} represents a counter ion which forms a salt in the presence of a base and solvent,


iv) neutralizing the compound of formula (XI) followed by enzymatic hydrolysis using conventional methods to produce APCA of formula (V),



v) silylating the APCA of formula (V) using a mixture of trimethyl silylchloride and hexamethyl disilazane in the presence of a halogenated solvent to produce silylated APCA of formula (XII) and



vi) condensing the silylated derivative of APCA of the formula (XII) with the mixed anhydride of the formula (XIII)



wherein R_2 represents alkyl, phenyl, benzyl or cycloalkyl and R_3 represents methyl, ethyl or isopropyl, in the presence of a halogenated solvent and a base at a temperature in the range of $-70\text{ }^{\circ}\text{C}$ to $10\text{ }^{\circ}\text{C}$ to produce cefprozil DMF solvate of formula (I).

2. The process as claimed in claim 1, wherein the carboxy protecting group represented by R_1 is selected from methyl, ethyl, propyl, isopropyl, p-methoxybenzyl, p-nitrobenzyl, o-chlorobenzyl, diphenylmethyl and the like.


3. The process as claimed in claim 1, wherein the solvent used for the reaction with acetaldehyde in step (i) is selected from DMF, isopropyl alcohol, methylene chloride, acetonitrile and the like or mixtures thereof.

4. The process as claimed in claim 1, wherein the solvent used for deesterification in step (ii) is selected from methylene chloride, ethyl acetate, water or mixture thereof.

5. The process as claimed in claim 1, wherein the deesterification in step (ii) is carried out using phenol/trifluoroacetic acid, anisole/trifluoroacetic acid, formic acid using solvent such as methylene chloride, ethyl acetate, water or mixtures thereof.


6. The process as claimed in claim 1, wherein the solvent used in step (iii) is selected from water, acetone, DMF, THF, DMAc, DMSO, halogenated alkane like methylene chloride, ethylene chloride, CCl_4 , CHCl_3 or mixtures thereof.

7. The process as claimed in claim 1, wherein the base used in step (iii) is selected from sodium hydroxide, lithium hydroxide, potassium hydroxide, ammonium hydroxide or organic base selected from tertiary butyl amine, benzyl amine, dibenzyl amine, triethyl amine, diethyl amine, dicyclohexyl amine, cyclohexyl amine or benzothiazole.
8. The process as claimed in claim 1, wherein the halogenated solvent used in step (v) is selected from methylene chloride, ethylene chloride, CCl_4 or CHCl_3 .
9. The process as claimed in claim 1, wherein the halogenated solvent used in step (vi) is selected from methylene chloride, ethylene chloride, CCl_4 or CHCl_3 .
10. The process as claimed in claim 1, wherein the base used in step (vi) is selected from triethylamine, N-methyl morpholine or diethylamine.
11. An intermediate of formula (XI)



wherein M^+ represents a counter ion which forms a salt.

12. An intermediate as claimed in claim 11, wherein the counter ion represented by M^+ is selected from sodium, lithium, potassium, ammonium, tertiary butyl amine, benzyl amine, dibenzyl amine, diethyl amine, triethyl amine, dicyclohexyl amine, cyclohexyl amine or benzothiazole.
13. A process for the preparation of cefprozil of the formula (XIV)



from cefprozil DMF solvate of the formula (I) prepared by the process as claimed in any of the preceding claims.

INTERNATIONAL SEARCH REPORT

PCT/IB 02/05459

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D501/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 694 079 A (CRAST JR LEONARD B) 15 September 1987 (1987-09-15) cited in the application the whole document ---	1-13
A	US 5 869 648 A (PRAGER BERNHARD ET AL) 9 February 1999 (1999-02-09) cited in the application the whole document ---	1-13
A	US 4 112 087 A (BEEBY PHILIP J) 5 September 1978 (1978-09-05) column 26, line 57-59 -----	11,12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *a* document member of the same patent family

Date of the actual completion of the international search

9 July 2003

Date of mailing of the international search report

16/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grassi, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/IB 02/05459

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4694079	A	15-09-1987	AT	389876 B	12-02-1990
			AT	202886 A	15-07-1989
			CA	1262345 A1	17-10-1989
			CN	86105568 A ,B	01-04-1987
			CS	8605613 A2	17-09-1987
			DD	248594 A5	12-08-1987
			EG	18112 A	30-08-1992
			ES	2001338 A6	16-05-1988
			FI	863066 A ,B,	30-01-1987
			GR	861988 A1	22-12-1986
			HU	41799 A2	28-05-1987
			KR	9304014 B1	19-05-1993
			NO	862970 A ,B,	30-01-1987
			PT	83074 A ,B	01-08-1986
			SU	1414317 A3	30-07-1988
			YU	131086 A1	31-10-1987
<hr/>					
US 5869648	A	09-02-1999	AT	399876 B	25-08-1995
			US	6136967 A	24-10-2000
			US	6333409 B1	25-12-2001
			AT	19192 A	15-12-1994
			AT	205214 T	15-09-2001
			DE	69232048 D1	11-10-2001
			DE	69232048 T2	04-07-2002
			DK	630380 T3	10-12-2001
			WO	9316084 A1	19-08-1993
			EP	1029864 A1	23-08-2000
			EP	1103555 A1	30-05-2001
			EP	0630380 A1	28-12-1994
			ES	2162812 T3	16-01-2002
			GR	3036985 T3	31-01-2002
			JP	2825655 B2	18-11-1998
			JP	7503474 T	13-04-1995
PT	630380 T	28-02-2002			
SG	48415 A1	17-04-1998			
<hr/>					
US 4112087	A	05-09-1978	NONE		
<hr/>					

THIS PAGE BLANK (USPTO)